Pain management by chemogenetic control of sensory neurons.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38118411.
- Also identified by DOI 10.1016/j.xcrm.2023.101338 and PMC identifier 10772549.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this study, Perez-Sanchez et al.<sup>1</sup> developed a chemogenetic method aimed at alleviating pain in mouse models while dampening excitability in human sensory neurons. This analgesic effect was attained through the introduction of human α7 nicotinic acetylcholine receptor and glycine receptor pore domain via virus-mediated expression in sensory neurons, forming a chloride channel. The activation of this channel was made possible by specific agonists. This study highlights the potential for treating clinical pain by gene therapy.
Medical subject headings
- Pain Management
- Sensory Receptor Cells